BBP-398
As of the edition of 20 October 2026, BBP-398 is a small molecule: stopped in 2024; acts on PTPN11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 6, 6 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of BBP-398.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTPN11 | Tyrosine-protein phosphatase non-receptor type 11 | Q06124 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 0 | 0 | 5 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Navire Pharma | Lead sponsor of trials | 2020 to now |
| LianBio | Lead sponsor of trials | 2022 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2023 to now |